Abstract LBA37
Background
Immunotherapy based combinations recently revolutionized the treatment of patients (pts) with advanced HCC, but its significance in earlier stages remains to be determined. TACE is commonly used as first line treatment in intermediate HCC, but outcome of pts treated with TACE in real-life cohorts is still poor with a median overall survival (OS) below 20 months. The release of neoantigens following local treatments is projected to trigger synergistic effects with anti-PD-1 antibodies, thus providing a rational for the combination of immunotherapy with TACE. The aim of this study was to determine the safety and efficacy of TACE with nivolumab.
Methods
This is a phase II trial, that recruited 59 pts at 10 sites in Germany between 06/2018 and 06/2020. Pts received up to 2 TACE treatments followed by nivolumab (240 mg/ Q2W), initiated on day 2-3 after the first TACE session and continued until progression for a maximum treatment duration of two years. One additional local treatment was allowed upon first progression. Primary endpoint (EP) was ORR (mRECIST; with an ORR exceeding 55% as promising for further investigations). Secondary EPs include PFS, TTFS, OS, QoL, and safety/tolerability. Tumor tissue was obtained at baseline and blood samples were collected longitudinally and subjected to an extensive biomarker analysis.
Results
49 pts (14.3% HCV and 8.2% HBV) were enrolled and received at least one dose of nivolumab. Median tumor size was 3 cm (0.6 – 14.7 cm) and median no. 3 (1 – 12). ORR was 71%. At a median follow-up of 14.6 months, mPFS was 6.14 mo (95% CI; 5.16 – 7.56; 41 events). Provisional mOS was 28.32 mo (95% CI; 20.60 – not estimable; 18 events). Grade ≥3 treatment-related adverse events occurred in 34.7% of pts. Correlative analysis of efficacy with genetic alterations, gene expression signatures and immune cell populations is ongoing.
Conclusions
The study met its primary EP and provides evidence for the efficacy of TACE in combination with nivolumab without new safety signals in pts with intermediate HCC and no prior systemic therapy. Our findings support further evaluation of nivolumab-based combinations for the treatment of intermediate HCC.
Clinical trial identification
NCT03572582; AIO-HEP-0217.
Editorial acknowledgement
Legal entity responsible for the study
AIO-Studien-gGmbH.
Funding
BMS.
Disclosure
A. Vogel: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: Sanofi; Financial Interests, Personal, Invited Speaker: BMS; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Eisai; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Personal, Invited Speaker: Incyte; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Invited Speaker: PierreFabre; Financial Interests, Personal, Advisory Board: PierreFabre; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Invited Speaker: Lilly; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: MSD; Financial Interests, Personal, Invited Speaker: Beigene; Financial Interests, Personal, Invited Speaker: Jiangsu Hengrui Medicines. A. Saborowski: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Invited Speaker: Servier; Financial Interests, Personal, Invited Speaker: BMS. T.J. Ettrich: Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: BMS; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Servien; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Celgene; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Sanofi Aventis. U. Ehmer: Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: AstraZeneca; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Bayer; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Eisai; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Ipsen; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Lilly; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Roche; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: AstraZeneca; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Eisai; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Ipsen; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: MSD; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Roche; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Sirtex. U.M. Martens: Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: BMS; Financial Interests, Personal, Other, Receipt of honoraria or consultation fees: Roche; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: BMS; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: MSD; Financial Interests, Personal, Other, Performing work in clinical trials / financial support: Roche. T. Berg: Financial Interests, Personal, Other, Receipt of grants / research support: AbbVie; Financial Interests, Personal, Other, Receipt of grants / research support: BMS; Financial Interests, Personal, Other, Receipt of grants / research support: Gilead; Financial Interests, Personal, Other, Receipt of grants / research support: MSD/Merck; Financial Interests, Personal, Other, Receipt of grants / research support: Humedics; Financial Interests, Personal, Other, Receipt of grants / research support: Intercept; Financial Interests, Personal, Other, Receipt of grants / research support: Merz; Financial Interests, Personal, Other, Receipt of grants / research support: Novartis; Financial Interests, Personal, Other, Receipt of grants / research support: Sequana Medical; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: AbbVie; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Alexion; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Bayer; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Gilead; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: GSK; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Eisai; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Enyo Pharma; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: HepaRegeniX GmbH; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Humedics; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Intercept; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Ipsen; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Janssen; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: MSD/Merck; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Novartis; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Roche; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Sequana Medical; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: SIRTEX; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: SOBI; Financial Interests, Personal, Other, Receipt of honoraria or consultaion fees/advisory board: Shionogi; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: AbbVie; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Alexion; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Bayer; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Gilead; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Eisai; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Intercept; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Ipsen; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Janssen; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: MedUpdate GmbH; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: MSD/Merck; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Novartis; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: Sequana Medical; Financial Interests, Personal, Other, Participation in a company sponsored speakers bureau: SIRTEX; Non-Financial Interests, Personal, Other, Non-remunerated membership or affiliation: DGVS; Non-Financial Interests, Personal, Other, Non-remunerated membership or affiliation: EASL; Non-Financial Interests, Personal, Other, Non-remunerated membership or affiliation: AASVD. D. Waldschmidt: Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: AstraZenecaCompany; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Bayer Health Pharma; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: BMS; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Celgene; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Eisai; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Incyte; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Ipsen; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Falk; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: MSD; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Novartis; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Roche Pharma AG; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Servier; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Shire Baxelta; Financial Interests, Personal, Other, Receipt of honoria or consultaion fees: Sirtex; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: AstraZenecaCompany; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Bayer Health Pharma; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: BeiGene; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: BMS; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Celgene; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Eisai; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Incyte; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Ipsen; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: MSD; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Pharmacyclics; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Roche Pharma AG; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Servier; Financial Interests, Personal, Other, Performing work in clinical trials/financial support: Sirtex; Financial Interests, Personal, Other, Non-remunerated membership or affiliation: AIO; Financial Interests, Personal, Other, Non-remunerated membership or affiliation: ASCO; Financial Interests, Personal, Other, Non-remunerated membership or affiliation: DGHO; Financial Interests, Personal, Other, Non-remunerated membership or affiliation: DGIM; Financial Interests, Personal, Other, Non-remunerated membership or affiliation: DGVS; Financial Interests, Personal, Other, Non-remunerated membership or affiliation: DKG. All other authors have declared no conflicts of interest.
Resources from the same session
LBA52 - Sintilimab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced or metastatic esophageal squamous cell cancer: First results of the phase III ORIENT-15 study
Presenter: Lin Shen
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA53 - Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
Presenter: Jianming Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): Results of the randomized phase II INTEGA trial (AIO STO 0217)
Presenter: Alexander Stein
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA55 - Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
Presenter: Eric Van Cutsem
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
1373MO - JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Rui-Hua Xu
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
LBA10 - Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group
Presenter: Lukas Perkhofer
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
Discussion LBA52, LBA53, LBA54 and LBA55
Presenter: Yelena Janjigian
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
Discussion 1373MO, LBA10 and LBA37
Presenter: Changhoon Yoo
Session: Mini oral session - Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast